Date Title and Summary Additional Formats
Toggle Summary Nantworks To Present Healthcare And Biotechnology Platforms At 36th Annual J.P. Morgan Healthcare Conference On January 9, 2018 In San Francisco, CA
Announces a Record 25 Letters of Authorization to Proceed with Clinical Trials Covering 12 Novel Biological Molecules in 20 Tumor Types January 5, 2018 — Culver City, California — NantWorks , the parent organization of NantHealth (NASDAQ: NH) and NantKwest (NASDAQ: NK) announced today that Dr.
Toggle Summary Partnership enables rapid and efficient start-up of 15,000 research sites nationwide
CULVER CITY, Calif. – March 22, 2016 – Cancer Moonshot 2020 , the nation's most comprehensive cancer collaborative initiative formed to accelerate next-generation immunotherapy in cancer, announced today the selection of Schulman IRB as its national institutional review board (IRB) of record.
Toggle Summary Patrick Soon-Shiong, MD, to Deliver Cancer Moonshot 2020 Keynote at Biocom Global Life Science Partnering Conference
La Jolla, CA – February 24, 2016 –Patrick Soon-Shiong, M.D., founder and CEO of NantWorks , LLC, and leader of the Cancer MoonShot 2020 program, will deliver the keynote session, “Cancer Moonshot 2020 & The National Immunotherapy Coalition,” at the sixth annual Biocom Global Life Science
Toggle Summary Progress Report on Cancer Breakthroughs 2020 Project Presented by Dr. Soon-Shiong at J.P. Morgan Healthcare Conference
Complete Responses Noted in Multiple Tumor Types (including Pancreatic Cancer, Triple Negative Breast Cancer, Head and Neck Cancer, Merkel Cell Cancer, Bladder Cancer, and Non-Hodgkin’s Lymphoma) when Natural Killer cells and T cells are activated simultaneously FDA Registrationfilings in Bladder,
Toggle Summary San Diego key part of program to beat cancer by 2020
Soon-Shiong taps biotech hub for talent, biomedical manufacturing prowess By Bradley J. Fikes (/staff/bradley-fikes/) | 3:33 p.m. March 3, 2016 If physician turned billionaire biotech entrepreneur Dr. Patrick Soon-Shiong succeeds in his ambitious goal to defeat cancer by 2020, San Diego County's
Toggle Summary Sorrento and Conkwest Announce Exclusive Global Collaboration Developing Next Generation Cancer Immunotherapy with “Off-the-Shelf” Chimeric Antigen Receptor–Tumor Attacking Natural Killer (CAR-taNK™) Cell Lines
San Diego and Cardiff-by-the-Sea, CA (Dec. 19, 2014) — Sorrento Therapeutics, Inc. (NASDAQ: SRNE; Sorrento), an oncology company developing new treatments for cancer and associated pain, and Conkwest, Inc., a privately-held immuno-oncology company developing proprietary Neukoplast ® , a Natural